NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today as part of its commitment to oncology that it expects to start a total of seven Phase 3 studies in 2008; two are open and enrolling, and five are planned to begin by the end of 2008. These trials involve three different compounds: Sutent, axitinib and CP-751,871, and will focus on 4 types of cancers – hepatocelluar (HCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and prostate cancer. Pfizer made these announcements during a company meeting with financial analysts during the Annual American Society of Clinical Oncology (ASCO) in Chicago.
